Peginteferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 [2] (multiple letters)

Hepatology

Volumn 40, Issue 3, 2004, Pages 760-761

  Pijak, Michal R ^a   Gazdik, Frantisek ^a   Hrusovsky, Stefan ^a   Jeffers, Lennox J ^b   Cassidy, William ^c   Howell, Charles D ^d   Hu, Sylvia ^e   Reddy, K Rajender ^f  

^a SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e HOFFMANN LA ROCHE INC   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A;

AFRICAN AMERICAN; BODY MASS; BODY WEIGHT; COMORBIDITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VIRUS LOAD; WEIGHT REDUCTION; CLASSIFICATION; NOTE; VIROLOGY;

AFRICAN AMERICANS; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL;

EID: 4544229961     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20397     Document Type: Letter

References (0)